Allogene Therapeutics Inc (NAS:ALLO)
$ 2.07 -0.01 (-0.48%) Market Cap: 432.18 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.76 GF Score: 28/100

Q3 2022 Allogene Therapeutics Inc Earnings Call Transcript

Nov 02, 2022 / 09:00PM GMT
Release Date Price: $10.17 (-3.78%)
Operator

Hello, and thank you for standing by, and welcome to Allogene Therapeutics Third Quarter of 2022 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Thank you, operator, and welcome to our Q3 call.

After market close, we issued a business update and financial results press release for the third quarter of 2022. This press release and today's webcast are available on our website. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many as possible. Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot